london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Time-domain OCT and spectral domain OCT in neovascular age-related macular degeneration

Poster Details

First Author: A.Ozkaya TURKEY

Co Author(s):    Z. Alkin   Y. Karakucuk   A.T. Yazici   A. Demirok         0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the ability of spectral-domain optical coherence tomography to detect subtle amounts of retinal fluid when the choroidal neovascularization is detected as inactive via time-domain optical coherence tomography and clinical examination in patients with neovascular age-related macular degeneration (nAMD).

Setting:

Beyoglu Eye Training and Research Hospital

Methods:

Forty-nine eyes of 49 patients with nAMD after ranibizumab treatment were included in this cross-sectional, prospective study. All patients were imaged with TD-OCT and SD-OCT at the same visit one month after a ranibizumab injection. The presence of subretinal, intraretinal, and subretinal pigment epithelium fluid (subRPE) in SD-OCT was evaluated; also mean central retinal thickness and the rate of vitreoretinal surface disorders detected via the two devices were evaluated.

Results:

The mean CRT of the patients via TD-OCT and SD-OCT was 218.1±51.3 microns (range 139-418 microns), and 325.7±78.8 (range 222-508 microns). The mean ratio between the mean CRT measured with SD-OCT and TD-OCT was 1.51 ± 0.09. Sixteen patients (32.6%) showed subretinal, intraretinal, or subRPE fluid via SD-OCT. In detail; 8 patients showed (%16.3) subretinal fluid, 10 patients (%20.4) showed intraretinal fluid, and 3 patients (%6.1) showed SubRPE fluid. The ability of detecting vitreoretinal surface disorders was comparable between the two devices, except vitreomacular traction.

Conclusions:

SD-OCT is essential for the nAMD patients who are on an as-needed treatment regimen with ranibizumab. Only TD-OCT and clinical examination may cause insufficient treatment in this group of patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy